CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

As an obesity treatment, Wegovy, made by Novo Nordisk, comes with a slightly higher dose for treating obesity than doses for diabetes; the medication is otherwise the same. For Zepbound ...

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid or state employee insurance programs are scrambling to lessen the ...

Zepbound is a newer weight loss medication joining the ranks of Wegovy and Saxenda. It’s a brand name for tirzepatide, which manufacturers also sell as a drug for type 2 diabetes under the name ...

Medications targeting weight loss like Wegovy and Zepbound are part of a relatively new class of drugs that work by suppressing appetite and food intake. They’ve been hailed as not only life-changing ...

Due to current legislation regarding weight loss drugs, Medicare Part D or Part C plans with drug coverage may only cover Zepbound for ... after the FDA approved Wegovy (Semaglutide) for treating ...

The drugs were first used to treat diabetes but drugmakers have introduced newer brands such as Wegovy and Zepbound approved for people with obesity. Medicare currently covers GLP-1 drugs such as ...

(CNN) — The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on ...

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to get out from under the budgetary squeeze that took them ...